Status:
UNKNOWN
Adoptive Cell Therapy Following Non-myeloablate Chemotherapy in Metastatic Melanoma Patients
Lead Sponsor:
Sheba Medical Center
Conditions:
Metastatic Melanoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Metastatic melanoma is an aggressive and highly malignant cancer. The five-year survival rate of patients with metastatic disease is less than 5% with a median survival of only 6-10 months. Drugs like...
Eligibility Criteria
Inclusion
- Metastatic Melanoma patients failing to prior chemo and immunotherapy with good performance status.
Exclusion
- Brain mets
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2013
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT00287131
Start Date
January 1 2006
End Date
November 1 2013
Last Update
March 29 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sheba Medical Center
Tel Litwinsky, Tel Hashomer, Israel, 52621